HIGHLIGHTS
- who: Andrew J. Weickhardt from the Department of Medical Oncology, Austin Health, Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, VIC, Australia have published the research: Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer, in the Journal: (JOURNAL)
- what: The aim of this study was to identify mechanisms of to inhibitors in two previously uncharacterised cell lines harbouring fusions and assess rational combination therapies to enhance sensitivity to these agents. The authors demonstrate that increased expression of pERBB3 is a key mechanism of adaptive . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.